Sacks K L, Olweny C, Mann D L, Simon R, Johnson G E, Poplack D G, Leventhal B G
Cancer Res. 1975 Dec;35(12):3715-20.
Patients in remission with advanced acute lymphatic leukemia were randomly assigned to receive chemotherapy alone or chemotherapy plus immunotherapy with a Burkitt lymphoma tissue culture cell line (RAJI). Remission duration in both groups were identical. Complement-dependent cytotoxic antibody was seen in 5 of 8 immunized patients and 0 of 8 controls. This antibody reacted with RAJI and both allogeneic and autologous acute leukemia cells. Antibody titers began to rise after 2 months, peaked at 4 months, and then declined prior to relapse in all patients. The time course of the increase in mixed-leukocyte culture response to RAJI was similar to immunized patients. An increased in vitro response to phytohemagglutinin was seen during drug administration in all patients. Although no clinical benefit was seen in this small number of patients with the RAJI injections, these in vitro responses are encouraging and new immunization schedules will be investigated.
晚期急性淋巴细胞白血病缓解期患者被随机分配接受单纯化疗或化疗加用伯基特淋巴瘤组织培养细胞系（RAJI）进行免疫治疗。两组的缓解期相同。8例接受免疫治疗的患者中有5例出现补体依赖性细胞毒性抗体，而8例对照组患者中未出现。该抗体与RAJI以及同种异体和自体急性白血病细胞发生反应。抗体滴度在2个月后开始上升，4个月时达到峰值，然后在所有患者复发前下降。对RAJI的混合淋巴细胞培养反应增加的时间进程与接受免疫治疗的患者相似。所有患者在给药期间对植物血凝素的体外反应均增强。虽然在这少数接受RAJI注射的患者中未观察到临床益处，但这些体外反应令人鼓舞，将研究新的免疫接种方案。
